Royal Bank of Canada
ACIU icon

Royal Bank of Canada’s AC Immune ACIU Stock Holding History

Royal Bank of Canada’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Buy
1,289
+429
+50% +$1.18K ﹤0.01% 7036
2026
Q1 		$2K Buy
860
+2
+0.2% +$6 ﹤0.01% 6655
2025
Q4 		$2K Sell
858
-950
-53% -$3K ﹤0.01% 6881
2025
Q3 		$5K Buy
1,808
+220
+14% +$497 ﹤0.01% 6676
2025
Q2 		$3K Sell
1,588
-72
-4% -$125 ﹤0.01% 6718
2025
Q1 		$3K Buy
1,660
+675
+69% +$1.7K ﹤0.01% 6456
2024
Q4 		$3K Buy
985
+225
+30% +$703 ﹤0.01% 6622
2024
Q3 		$3K Hold
760
– – ﹤0.01% 6575
2024
Q2 		$3K Sell
760
-1,227
-62% -$4.06K ﹤0.01% 6636
2024
Q1 		$6K Sell
1,987
-11,437
-85% -$41K ﹤0.01% 6368
2023
Q4 		$68K Buy
13,424
+10,647
+383% +$34.2K ﹤0.01% 5836
2023
Q3 		$8K Sell
2,777
-522
-16% -$1.59K ﹤0.01% 6480
2023
Q2 		$10K Buy
3,299
+2,119
+180% +$4.63K ﹤0.01% 6462
2023
Q1 		$3K Hold
1,180
– – ﹤0.01% 6666
2022
Q4 		$2K Buy
1,180
+180
+18% +$464 ﹤0.01% 6906
2022
Q3 		$3K Sell
1,000
-3,600
-78% -$11.3K ﹤0.01% 6866
2022
Q2 		$17K Sell
4,600
-2,200
-32% -$7.53K ﹤0.01% 6170
2022
Q1 		$27K Sell
6,800
-5,859
-46% -$25.4K ﹤0.01% 6437
2021
Q4 		$62K Sell
12,659
-2,239
-15% -$13K ﹤0.01% 6236
2021
Q3 		$100K Sell
14,898
-106
-0.7% -$759 ﹤0.01% 5698
2021
Q2 		$119K Sell
15,004
-10,579
-41% -$73.1K ﹤0.01% 5489
2021
Q1 		$195K Buy
25,583
+24,673
+2,711% +$176K ﹤0.01% 4973
2020
Q4 		$4K Buy
910
+721
+381% +$3.68K ﹤0.01% 6714
2020
Q3 		$1K Buy
+189
New +$1.36K ﹤0.01% 6377
2019
Q4 		– Sell
-491
Closed -$2K – 6768
2019
Q3 		$2K Buy
491
+238
+94% +$1.27K ﹤0.01% 6262
2019
Q2 		$1K Sell
253
-177
-41% -$902 ﹤0.01% 6667
2019
Q1 		$2K Buy
+430
New +$2.73K ﹤0.01% 6492

Other funds holding ACIU

Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada's ACIU Position: Q2 2026 in Review

Royal Bank of Canada increased its AC Immune (ACIU) stake by 50% in Q2 2026, buying an estimated $1.18K and bringing the position to 1,289 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #7036.

Royal Bank of Canada first reported a position in ACIU in Q1 2019 and has held it in 27 quarters since. The position peaked at $195K in Q1 2021. 40 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.

  • Royal Bank of Canada held 1,289 shares of AC Immune worth $3K as of Q2 2026.
  • Royal Bank of Canada bought 429 AC Immune shares in Q2 2026, an estimated $1.18K.
  • AC Immune made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7036 holding.
  • Royal Bank of Canada first reported a position in AC Immune in Q1 2019 and has held it in 27 quarters since.
  • Royal Bank of Canada's AC Immune position peaked at $195K in Q1 2021.
  • 40 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.